About Orcosa
Orcosa develops experimental medicines for people who struggle with conventional pills. Its small oral tablets break apart quickly and carry a measured dose. This format avoids swallowing a whole pill, needing water or measuring a liquid.
Based in Ewing, New Jersey, Orcosa is led by co-founder and chief executive officer Bryan Ridall. Its lead candidate, ORC-144, is an investigational cannabidiol tablet for acute pain in adults. The candidate lacks FDA approval, and its safety and effectiveness remain unestablished for the uses under study.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 15, 2026 | Nov 12, 2026 | $6,000,000of $11.5M target | 25 | $240K | EquityRule 506(b) | Form D ↗ |
| Dec 23, 2024 | Jan 7, 2025 | $7,275,000of $15.5M target | 17 | $427K | EquityRule 506(b) | Form D ↗ |
| Sep 27, 2021 | Oct 12, 2021amended Jan 7, 2025 | $11,290,750fully sold | 36 | $313K | Options, Simple Agreements for Future EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, three offerings | $24,565,750 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
What the SEC Filings Show
- Mark Ridall was last listed as a director on the Form D that Orcosa filed on October 12, 2021. [9]Form D filings that name Mark Ridall (2):
- Orcosa, CEO and director: Mar 19, 2021 · Oct 12, 2021
Why Investors Backed Orcosa
Conventional dosing can burden people who cannot swallow intact pills or caregivers who must measure liquids. Orcosa has combined in-house development and manufacturing with clinical research and patent protection around its delivery design. [1][3]
Origin and Team
Bryan Ridall, Vincent T. Mileto and Robert M. Pollaro co-founded Orcosa. [2]
Ridall brought more than a decade of pharmaceutical work focused on delivery technologies. He had developed medicines for veterinary FDA approval and led a consultancy for emerging drug companies. [2]
Mileto brought more than two decades in pharmaceuticals, including quality assurance, operations and commercial manufacturing. [2]
Pollaro brought more than 20 years as a lawyer and intellectual property strategist. He previously served as special counsel at Cadwalader, Wickersham & Taft. [2]
Product and Technology
RITe pairs rapid tablet breakup with one fixed dose and tailors the formulation to both the medicine and its user. Each tablet disintegrates in roughly five seconds. [1]
ORC-144 is an investigational cannabidiol tablet intended as a non-opioid treatment for acute pain in adults. A randomized, double-blind shoulder-surgery study found less pain on day one. Participants also reported greater satisfaction with pain control on days one and two. At one year, follow-up found no significant differences between the ORC-144 and placebo groups in pain, satisfaction or reported shoulder outcomes. [1][3]
Orcosa’s patented packaging hermetically seals individual RITe tablets beneath a multilayer lid using thermoplastic polymer and aluminum barriers. The design limits light, moisture and oxygen exposure. It also resists child access while supporting product stability. [5]
Milestones
Scroll table to see all columns →
| Date | What happened | Source | Coverage |
|---|---|---|---|
| May 6, 2026 | Andy Drechsler joined as chief financial officer to align financial strategy and resources with development priorities. | [4] | — |
| Feb 27, 2026 | European Patent No. 4 243 797 added protection for ORC-144. | [3] | — |
| Aug 12, 2025 | Orcosa received U.S. Patent No. 12,383,494 covering protective packaging for fast-disintegrating tablets. | [5] | — |
| Jul 28, 2025 | Vincent Mileto received NJBIZ’s 2025 People to Watch in Health Care recognition. | [3] | — |
| Jun 30, 2025 | Orcosa appointed Kevin Kaplan chief medical officer. | [3] | — |
| Feb 5, 2024 | Orcosa reported one-year follow-up data for ORC-144 after the shoulder-surgery trial. | [3] | — |
| Jan 30, 2024 | Edward Sturchio and Robert Radie joined Orcosa’s Board of Directors as independent directors. | [3] | — |
| Jun 14, 2023 | Orcosa received U.S. Patent No. 11,672,761 supporting ORC-144 development. | [3] | — |
| Sep 9, 2022 | ORC-144 research was presented at the SECEC-ESSSE Congress. | [3] | — |
| Aug 1, 2022 | The randomized ORC-144 clinical trial was published in AJSM. | [3] | — |
| Jul 16, 2022 | ORC-144 research was presented at the AOSSM Annual Meeting. | [3] | — |
| Jul 14, 2022 | Former FDA Commissioner Andrew C. von Eschenbach joined Orcosa as senior advisor. | [3] | — |
| Mar 25, 2022 | ORC-144 research was presented at the AAOS Annual Meeting. | [3] | — |
We wrote this summary from public statements by Orcosa and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Orcosa's Form D filed Nov 12, 2026.
Earlier filings also listed Mark Ridall (ceo and director, last listed Mar 2021).
Sources
- CompanyOrcosa home and RITe platform · linked above ↑
- CompanyOrcosa company and leadership
- CompanyOrcosa news archive
- CompanyAndy Drechsler appointment
- CompanyRITe packaging patent announcement
- CompanyOrcosa privacy policy
- SECOrcosa Form D, filed 2026-11-12 · linked above ↑
- SECOrcosa Form D, filed 2025-01-07 · linked above ↑
- SECOrcosa Form D, filed 2021-10-12
- SECOrcosa Form D/A, filed 2025-01-07 · linked above ↑
- SECOrcosa Form D, filed 2021-03-19
- SECOrcosa Inc. filing history